The monthly European Industrial Pharmacists' newsletter September 2022

Technology & Research

ACT EU's Workplan 2022-2026

The Workplan 2022-2026 published by the European Commission, EMA and the HTA highlights the actions identified to pursued the ten priorities identified by ACT EU and provide a brief description of key deliverables and their associated timeline.

>>

Regulatory Affairs

Real-world evidence for regulatory decision-making

A ICRMA's joint statement and the new Big Data Workplan 2022-2025 jointly issued by EMA and HMA pave the way to the implementation of the use of big data analysis for regulatory decision-making. Some still open issues shall be address by discussion among the stakeholders, according to the detail timeline proposed in the workplan. >>

Business & Policies

EFPIA's Annual Report on the Pharmaceutical industry 2022

The Annual Report of the EFPIA indicates the sector is still in good health but suffers from the competition of more attractive economies. The length of the R&D process to reach the market together with regulatory barriers and the fragmentation typical of the European countries are still issues to be solved. >>

EU Focus

Patient involvement in the development, regulation and safe use of medicines

CIOMS report discusses the best practices that may be implemented along the entire lifecycle of a medicine to capture and consider the patient's point of view from the very early phase of development down to regulatory processing, and post-marketing monitoring. >>

News from EIPG

Webinar: Implementation of CCS Using the ECA template

The next EIPG webinar will be held in conjunction with PIER and University College Cork on Friday 21st of October 2022 (16.00 CEST), on the implementation of Contamination Control Strategy (CCS) using the ECA template. This is the second presentation on the CCS, given by Walid El Azab, an Industrial Pharmacist & a Qualified Person (QP) >>